Skip to main content
. Author manuscript; available in PMC: 2019 Oct 1.
Published in final edited form as: Curr Opin Endocr Metab Res. 2018 Feb 5;2:29–33. doi: 10.1016/j.coemr.2018.01.007

Figure 3. Effect of the monoclonal TSHR stimulatory antibody M22 on hyaluronan secretion in GOFs.

Figure 3

Adapted from (13). M22 stimulated hyaluronan secretion (HA) in a biphasic manner. The higher potency (lower concentrations of M22) phase was inhibited by the IGF1R inhibitor linsitinib whereas the lower potency (higher concentrations of M22) was not inhibited. A TSHR antagonist inhibited both phases of M22 stimulation (not shown here).